CONSORT 2025 refers to the updated version of the Consolidated Standards of Reporting Trials for reports of randomized trials. Developed by the CONSORT Group, this reporting guideline combines a checklist with a flow diagram and is intended for manuscripts presenting the results of a randomized trial. It specifies the information readers require to evaluate the participant journey and the results of a study.
Scope of CONSORT 2025
The guideline addresses the results report of a randomized controlled trial, rather than just the methods section or the abstract. Consequently, it considers the entire sequence from the title through recruitment, randomization, and analysis to the discussion. The flow diagram specifically visualizes how many individuals reached the stages of enrollment, allocation, follow-up, and analysis.
The 2025 version responds to developments in trial methodology and includes a restructured checklist with a section on Open Science. According to CONSORT sources, it comprises 30 essential items; alongside this, an expanded version is available, with sub-items explaining which information belongs to a specific checklist item. The accompanying “Explanation and Elaboration” document provides further clarification and examples.
Content Requirements for the Results Report
A CONSORT-compliant report describes the research question, the inclusion and exclusion criteria, the interventions, and the comparator arm in a way that makes the investigated allocation recognizable. Furthermore, it reports how the random allocation was generated and protected from bias, which endpoints were used, and which analysis population was applied. Deviations between planned and reported procedures must remain visible within their context.
For results, the guideline requires more than a p-value or a single effect size. Numbers for each group, estimates with precision, adverse effects, and reasons for missing data belong in the presentation, provided they are relevant to the study. The report is not intended to replace the trial protocol, but rather to provide a transparent account of its implementation and the data actually generated.
Distinction: Reporting Standard, Not Operational Requirement
CONSORT 2025 does not prescribe a randomized study design, nor does it decide which intervention, sample size, or statistical method is scientifically appropriate. These decisions are made before and during the study within the clinical trial protocol, statistical planning, and under applicable GCP and regulatory requirements. The checklist only applies to the question of whether a completed study manuscript fully discloses the decisions made.
In this respect, CONSORT is distinct from SPIRIT 2025. SPIRIT structures information within the protocol of a randomized trial, whereas CONSORT addresses the publication of its results. Both documents are jointly maintained standards but fulfill different functions along the trial continuum.
The checklist also serves a sequencing function: it prevents a study from reporting only the most favorable effect without stating the baseline characteristics of the groups and the number of individuals not analyzed. Information on registration, the full trial protocol, funding, and conflicts of interest situates the article beyond the actual result tables. The expanded checklist can serve as a working list for complex designs without turning the manuscript into a regulatory study report.
The guideline was published simultaneously in five journals. This joint publication underscores its character as a cross-disciplinary standard for authors, reviewers, and editors. However, it is not a formal regulatory requirement: a manuscript may reflect regulatory-compliant study data and yet lack essential CONSORT information. Conversely, a completed checklist does not guarantee that the study was free of methodological weaknesses.
Relevance for clinical trials
In a randomized trial, publication planning must link to the protocol and the analysis plan early enough. For the subsequent report, recruitment figures, timing of withdrawals, participant allocation, endpoint definitions, and analysis sets are required from different workstreams. Retrospective changes to endpoints, analyses, or the treated population are particularly prone to conflict; CONSORT makes these points verifiable in the results report.
Full-service CROs like Mediconomics support CONSORT-compliant reporting by coordinating the alignment between the trial protocol, statistical analysis plan, database extract, participant flow, and manuscript. Medical Writing can translate the checklist into a manuscript review, while Biostatistics verifies effect sizes, confidence intervals, and analysis populations against the tables and listings. Project Management collects the documented reasons for deviations from the involved study functions.
Frequently Asked Questions (FAQ)
Is CONSORT 2025 only intended for drug trials?
No. Its subject is randomized trials and their results reports; the checklist is therefore not limited to a specific product type. For specific trial situations, CONSORT extensions may be applicable.
Must the CONSORT flow diagram include every screened individual?
The diagram documents the progress of participants through the trial. Which stages are reported depends on the trial flow; central are the figures for allocation, follow-up, and analysis, as well as the reasons for dropouts.
Does the CONSORT checklist replace the clinical trial protocol?
No. The clinical trial protocol defines the study before it begins. CONSORT organizes information for the report on the conducted study and its results.
Regulatory References
- CONSORT 2025 Statement — Checklist and flow diagram for reporting randomized trials.
- CONSORT 2025 Explanation and Elaboration — Explains the checklist items and their application in manuscripts.
- ICH E6(R3) Good Clinical Practice — Establishes requirements for the planning, conduct, and documented results of trials.
- ICMJE Recommendations — Refer to CONSORT as the study-type-specific reporting guideline for randomized trials.